GRPR and prostate carcinoma: Their potential for imaging GRPR expression was evaluated through in vitro competition binding, positron emission tomography (PET) imaging, and ex vivo biodistribution studies in a preclinical prostate cancer model, and compared with a clinically validated GRPR agonist tracer, [68Ga]Ga-AMBA (Figure 1D).